News Releases

 
News Releases
  Date Title and Summary View
Nov 17, 2017
MOUNTAIN VIEW, Calif., Nov. 17, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Piper Jaffra...
Nov 7, 2017
-- Phase III ADVOCATE trial of avacopan remains on track to complete enrollment in mid-2018 -- -- Patient enrollment ongoing in registration-supporting trial for avacopan in the treatment C3 Glomerulopathy (C3G) -- -- Plan to launch registration-supporting trial for CCX140 in the treatment of Focal Segmental Glomerulosclerosis (FSGS) in the f...
Nov 3, 2017
-- Rapid reduction in kidney inflammation following avacopan treatment in patients with ANCA-Associated Vasculitis revealed by analysis of markers of kidney damage -- -- Podocyte protection demonstrated with CCR2 inhibitor CCX140, supporting differentiated potential treatment option for patients with Focal Segmental Glomerulosclerosis -- MOUN...
Nov 1, 2017
MOUNTAIN VIEW, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that the Company's third quarter 2017 financial results will be released after market close on Tuesday, November 7, 2017. Ch...
Sep 5, 2017
MOUNTAIN VIEW, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at three upcoming investor conferences in...
Aug 8, 2017
-- Pivotal Phase III ADVOCATE trial of avacopan on track to complete enrollment in mid-2018 as projected -- -- Launching second trial of avacopan in patients with C3 Glomerulopathy (C3G) -- -- Conference call today at 5:00 p.m. Eastern Time -- MOUNTAIN VIEW, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a b...
Jul 26, 2017
MOUNTAIN VIEW, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that the Company's second quarter 2017 financial results will be released after market close on Tuesday, August 8, 2017. Che...
Jun 6, 2017
-- Clinical Study Shows Drop in Proteinuria in Patients Treated with Avacopan for IgA Nephropathy (IgAN) -- -- Potential of CCR2 Inhibitor as a Therapeutic Treatment Option for FSGS Validated -- MOUNTAIN VIEW, Calif., June 06, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications ...
May 24, 2017
MOUNTAIN VIEW, Calif., May 24, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, announced today that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: ...
May 23, 2017
MOUNTAIN VIEW, Calif., May 23, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, announced today that the European Medicines Agency (EMA) has granted orphan medicinal product designation for avacopan (formerly CCX168) in t...
Page:
1
... NextLast
= add release to Briefcase